Format

Send to

Choose Destination
Ther Innov Regul Sci. 2020 Mar;54(2):283-292. doi: 10.1007/s43441-019-00055-9. Epub 2020 Jan 6.

Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.

Author information

1
Pfizer Healthcare Ireland, Citywest Business Campus, Dublin, Ireland.
2
Pfizer Limited, Walton Oaks, Dorking Road, KT20 7NS, Tadworth, Surrey, United Kingdom.
3
Pfizer Inc Collegeville, Collegeville, PA, USA.
4
Pfizer Limited, Walton Oaks, Dorking Road, KT20 7NS, Tadworth, Surrey, United Kingdom. judith.c.macdonald@pfizer.com.

Abstract

In the current pharmaceutical regulatory environment, patients continue to benefit from great advances in medical care. Sophisticated regulatory review systems have also evolved to ensure that safe and effective medicines are approved. However, these systems are not optimized in all countries. Gaps in individual regulatory agency capabilities together with duplication in non-value added national regulatory requirements, particularly in low- and middle-income countries (LMICs), can slow down regulatory approvals and therefore impede patient access to new medicines. These gaps exist despite the achievements in both regulatory convergence and harmonization of technical requirements by bodies such as the International Conference on Harmonization (ICH). There is a pressing need to strengthen regulatory review systems in emerging market economies as highlighted by the World Health Organization (WHO). These diverse challenges may seem overwhelming to individual national regulators, in part because of the sheer number of initiatives by multiple stakeholders, combined with a lack of information on concise practical actionable measures that can have a positive impact on review efficiency. This commentary presents 10 pillars that we believe represent the key hallmarks of strong regulatory review systems. Leveraging our internal company expertise at the global, regional, and country level across our entire product portfolio (both innovative and generic), we selected features proven to work in leading regulatory agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which are also relevant for other regulatory authorities, especially in LMICs.

KEYWORDS:

LMIC; RSS; regulatory; reliance; strengthening

PMID:
32072580
DOI:
10.1007/s43441-019-00055-9

Supplemental Content

Loading ...
Support Center